Entera Bio (ENTX) Liabilities and Shareholders Equity (2017 - 2026)

Entera Bio has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $13.1 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 39.22% year-over-year to $13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.2 million (up 35.74% YoY) and the FY2025 annual result came in at $16.0 million, up 70.32% from the prior year.
• Liabilities and Shareholders Equity retreated to $13.1 million in Q1 2026, from $16.0 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $22.3 million in Q1 2022 and troughed at $7.7 million in Q3 2024.
• A 5-year average of $14.0 million and a median of $13.1 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity tumbled 49.49% — and 2025, when it soared 124.87%.
• Tracing ENTX's Liabilities and Shareholders Equity over 5 years: stood at $13.1 million in 2022, then fell by 10.38% to $11.8 million in 2023, then dropped by 20.19% to $9.4 million in 2024, then soared by 70.32% to $16.0 million in 2025, then declined by 17.91% to $13.1 million in 2026.
• Business Quant data shows ENTX's Liabilities and Shareholders Equity at $13.1 million in Q1 2026, $16.0 million in Q4 2025, and $17.4 million in Q3 2025.